ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 276. Committee on Obstetric Practice. Committee on Obstetric Practice. CommitteeOpinionNão. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125(2):521-5. 277. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-38. 278. National Institute for Health and Clinical Excellence (NICE). Hypertension in pregnancy. London:RCOG Press; 2011. (NICE clinical guideline 107) 279. Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, et al. Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy. Can J Cardiol. 2018;34(5):526-31. 280. American College of Obstetricians and Gynecologists. ACOG Practice BulletinNão. 125: Chronic hypertension in pregnancy. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2012;119(2 Pt 1):396-407. 281. de Paola AAV, Montenegro S, Vieira MC. Livro-texto da Sociedade Brasileira de Cardiologia. 2ª ed. São Paulo:Ed Manole;2015. Cap.27. 282. Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev Cardiol. 2015;12(12):718-29. 283. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014 Feb;(2):CD002252. 284. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-17. 285. Magee LA, vonDadelszen P, Singer J, Lee T, Rey E, Ross S, et al. The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood pressure? Hypertension. 2016;68(5):1153-9. 286. Fitton CA, Steiner MF, Aucott L, Pell JP, Mackay DF, Fleming M, et al. In- utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017;35(11):2123-37. 287. Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. Pediatr Cardiol. 2015;36(7):1442-51. 288. Fisher SC, Van Zutphen AR,Werler MM, Lin AE, Romitti PA, Druschel CM, et al. Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension. 2017;69(5):798-805. 289. Food and Drug Administration (FDA). Pregnancy, lactation, and reproductive potential: labeling for human Prescription drug and biological products. Fed Regist.2014;79(233):72063-103. 290. Shimada C, Akaishi R, Cho K, Morikawa M, Kaneshi Y, Yamda T, et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertens Res. 2015;38(5):308-13. 291. Magee LA, Duley L. Oral beta-blockers for mild tomoderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003 Jul;(3):CD002863. 292. Ersbøll AS, Hedegaard M, Søndergaard L, Ersbøll M, Johansen M. Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG. 2014;121(5):618-26. 293. Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol (Copenh). 1980;95(4):540-5. 294. EasterlingTR.Pharmacologicalmanagementofhypertension inpregnancy. Semin Perinatol. 2014;38(8):487-95. 295. Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs. 2014;74(3):283-96. 296. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960-9. 297. Ahn HK, Nava-Ocampo AA, Han JY, et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens Pregnancy. 2007;26(2):179-87. 298. Ramos JG, Sass N, Costa SH. Preeclampsia. Rev Bras Ginecol Obstet. 2017;39(9):496-512. 299. Brasil.Ministério da Educação. Porta lEbserh/; MEAC-UFC. Maternidade escola Assis Chateaubriand daUniversidade Federal do Ceará. Protocolos e diretrizes terapêuticas.[Internet}. [Citado em 2018 jan 10]. Disponível em: www.ebserh.gov.br/web/meac-ufc/protocoços-e-pops 300. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006 Jul;(3):CD001449. 301. Swartz RH, Cayley ML, Foley N, Ladhani NN, Leffert L, Bushnell C, et al. The incidence of pregnancy related stroke: a systematic review andmeta- analysis. Int J Stroke. 2017;12(7):687-97. 302. Okusanya BO, Oladapo OT, Long Q, Lumbiganon P, Carroli G, Qureshi Z, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG. 2016;123(3):356-66. 303. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. 304. Townsend R, O’Brien P, Khalil A. Current best practice in themanagement oh hypertensive disorders in pregnancy. Integr Blood Press Control. 2016 Jul;9:79-94. 305. Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int. 2014 Jul;2014:297397. 306. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010 Aug;(8):CD001059. 307. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr;(2):CD004659. 308. World Health Organization (WHO). Recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva;2011. 309. RolnikDL,Wright D, Poon L, O'GormanN, Syngelaki A, de PacoMatallana C, et al. Aspirin versus placebo in pregnancies at high risk of preterm preeclampsia. N Engl J Med. 2017;377(7):613-22. 310. Sibai BM. Etiology and management of postpartum hypertension-pre- eclampsia. Am J Obstet Gynecol. 2012;206(6):470-5. 311. Magee L, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013 Apr;(4):CD004351. 312. US National Library of Medicine, Toxicology Data Network. Drugs and lactation database.[Internet]. [Cited in 2018 Jun 12]. Available from: http:// www.toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. 313. Noronha Neto C C, Maia SS, Katz L, Coutinho IC, Souza AR, Amorim MM. Clonidine versus Captopril for Severe Postpartum Hypertension: A Randomized Controlled Trial. PLoS One. 2017;12(1):e0168124. 314. Melo BC, AmorimMM, Katz L, Coutinho I, Veríssimo G. Epidemiological profile and postpartum outcome in severe preeclampsia. Rev Assoc Med Bras. 2009;55(2):175-80. 938